Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study to Investigate the Effect of YM150 on the Plasma Concentration of Digoxin in Healthy Subjects

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Astellas Pharma Inc
ClinicalTrials.gov Identifier:
NCT01514812
First received: January 18, 2012
Last updated: January 23, 2012
Last verified: January 2012

January 18, 2012
January 23, 2012
February 2006
April 2006   (final data collection date for primary outcome measure)
  • Cmax of digoxin assessed by its plasma concentration change [ Time Frame: for 24 hour after the last dose of each period ] [ Designated as safety issue: No ]
  • AUC of digoxin assessed by its plasma concentration change [ Time Frame: for 24 hour after the last dose of each period ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01514812 on ClinicalTrials.gov Archive Site
  • Changes in the blood coaggregation indexes such as PT(INR), aPTT and FXa [ Time Frame: before dosing and 5hr after dosing on days 4 and 8 and 24h and 48h after the last dose ] [ Designated as safety issue: No ]
  • Safety assessed by the incidence of adverse events, vital signs, 12-lead ECG and labo-tests [ Time Frame: for 10 days after dosing ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A Study to Investigate the Effect of YM150 on the Plasma Concentration of Digoxin in Healthy Subjects
A Double Blind, Randomized, Two Period Crossover Study To Determine The Effect of Multiple Doses of 120 MG Modified Release Formulation of YM150 on the Steady State Pharmacokinetics of Digoxin in Healthy Subjects

This study is to evaluate the effect of YM150 on the plasma concentration of digoxin in healthy subjects.

The study will be of a double blind, randomized, two period crossover design. Two treatments, digoxin in combination with YM150, and digoxin in combination with placebo, will be evaluated. Each subject will receive both treatments in random order. Placebo will be used to maintain the blind. Males and females will be equally divided over the treatment orders.

Subjects will be dosed with digoxin and either YM150 or placebo for 8 days to reach steady state. In the second period the subjects will receive digoxin and the alternate treatment. There will be a washout period of at least 10 days between the consecutive treatments. In both study periods the subjects will be admitted the day prior to study drug administration (Day 0). The subjects will be discharged on Day 10. Approximately one week after the last discharge, the subjects will return to the unit for a post study visit.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Healthy
  • Pharmacokinetic of Digoxin
  • Drug: YM150
    oral - modified release formulation of YM150
    Other Name: darexaban
  • Drug: placebo
    oral
  • Drug: digoxin
    oral
  • Experimental: YM150-placebo sequence group
    YM150+digoxin; Washout; Placebo+digoxin
    Interventions:
    • Drug: YM150
    • Drug: placebo
    • Drug: digoxin
  • Experimental: placebo-YM150 sequence group
    Placebo+digoxin; Washout; YM150+digoxin
    Interventions:
    • Drug: YM150
    • Drug: placebo
    • Drug: digoxin
Kadokura T, Groenendaal D, Heeringa M, Mol R, Verheggen F, Garcia-Hernandez A, Onkels H. Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin. Eur J Drug Metab Pharmacokinet. 2014 Mar;39(1):1-9. doi: 10.1007/s13318-013-0141-1. Epub 2013 Jun 11.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
24
April 2006
April 2006   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy, as judged by the investigator or sub-investigator based on the results of physical examinations and all tests
  • Body weight: male: ≥60 kg, <100 kg; female: ≥45.0 kg, <80.0 kg
  • BMI (at screening): ≥18.0, <30.0

Exclusion Criteria:

  • Female subjects of child-bearing potential, not practicing adequate methods to prevent pregnancies, like abstinence or double barrier methods
  • Known or suspected hypersensitivity / allergy to FXa inhibitors, digoxin, or heart glycosides in general or the constituents of the formulations used
  • History of and/or any sign or symptom indicating current abnormal hemostasis or blood dyscrasia, including but not limited to neutropenia, thrombocytopenia, thrombocytopathy, thromboasthenia, hemophilia, Von Willebrand's disease, and vascular purpura, bleeding gums, or frequent nose bleeding
  • Family history of congenital vascular malformation (e.g. Marfan's Syndrome) and/or bleeding disorder (e.g. hemophilia, Von Willebrand's disease, Christmas disease)
  • PT or aPTT at the screening visit outside the normal range
  • History of peptic ulcer or of any other organic lesion susceptible to bleed
  • Any surgical intervention (including tooth extraction) or trauma within the last 3 months preceding the initiation of the study
  • Any clinically significant history of upper gastrointestinal symptoms (such as nausea, vomiting, abdominal discomfort or upset, or heartburn) in the 4 weeks prior to admission to the Research Unit
  • Any clinically significant history of any other disease or disorder - gastrointestinal, cardiovascular, respiratory, renal, hepatic, neurological, dermatological, psychiatric or metabolic
  • Any of the liver function tests (ALAT, ASAT, LDH and γ-GT) above the upper limit of normal range (ULN)
  • Any clinically significant abnormality following the investigator's review of the prestudy physical examination, ECG and clinical laboratory tests
  • Abnormal pulse rate and blood pressure measurements at the pre-study visit as follows: Pulse rate <40 or >90 bpm; systolic blood pressure <95 or >160 mmHg; diastolic blood pressure <40 or >95 mmHg (measurements taken after subject has been resting in supine position for 5 min)
  • Regular use of any prescribed or OTC (over-the-counter) drugs (including natural and herbal remedies and especially those with P-gp inhibiting activity, like St. John's worth) in the four weeks prior to admission to the Research Unit OR any use of such drugs (including natural and herbal remedies) as well as vitamins in the two weeks prior to admission to the Research Unit
  • Donation of blood or blood products within 3 months prior to admission to the Research Unit
Both
18 Years to 55 Years
Yes
Contact information is only displayed when the study is recruiting subjects
France
 
NCT01514812
150-CL-007, 2004-004930-15
No
Astellas Pharma Inc
Astellas Pharma Inc
Not Provided
Study Chair: Use Central Contact Astellas Pharma Inc
Astellas Pharma Inc
January 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP